^
    18h
    A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer (clinicaltrials.gov)
    P1, N=328, Recruiting, HC Biopharma Inc.
    New P1 trial
    |
    EGFR mutation
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • pemetrexed • etoposide IV
    21h
    SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2/3, N=30, Recruiting, Second Affiliated Hospital of Nanchang University | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Apr 2025
    Enrollment open • Trial initiation date
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed
    2d
    Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. (clinicaltrials.gov)
    P2, N=36, Recruiting, Guangzhou Medical University | Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Mar 2027
    Enrollment open • Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • pemetrexed • simmitinib (SYHA1817)
    2d
    IMPT Dose Escalation for NSCLC (HyDose) (clinicaltrials.gov)
    P=N/A, N=87, Recruiting, University Medical Center Groningen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • docetaxel • pemetrexed
    2d
    A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • carboplatin • gemcitabine • Tyvyt (sintilimab) • pemetrexed • uliledlimab (TJD5)
    2d
    STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1021, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK mutation • RET mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    3d
    Evaluating the Efficacy and Safety of Trilaciclib in Patients Receiving First-line Sintilimab Plus Chemotherapy for Advanced Driver Gene-negative Non-squamous Non-Small Cell Lung Cancer (ChiCTR2600117016)
    P=N/A, N=80, Not yet recruiting, Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University
    New trial
    |
    carboplatin • Tyvyt (sintilimab) • pemetrexed • Cosela (trilaciclib)
    3d
    Chemotherapy plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer: An Exploratory Phase I Trial (ChiCTR2600116912)
    P=N/A, N=22, Not yet recruiting, Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
    New trial
    |
    cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • pitavastatin
    3d
    Expression of B7-H3 in patients with advanced HIV-positive NSCLC and analysis of the efficacy and safety of immune checkpoint inhibitors combined with platinum-based dual drugs in the treatment of advanced HIV-positive NSCLC patients (ChiCTR2500113288)
    P=N/A, N=60, Completed, Guiyang Public Health Clinical Center; Guiyang Public Health Clinical Center
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD4 (CD4 Molecule)
    |
    EGFR negative
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed
    3d
    Prospective, Single-Center, Single-Arm Clinical Study of Ivosidenib (AK112) Combined with Chemotherapy for Neoadjuvant Treatment of Locally Advanced Oral Squamous Cell Carcinoma (ChiCTR2600117076)
    P4, N=15, Not yet recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university
    New P4 trial
    |
    carboplatin • paclitaxel • docetaxel • pemetrexed • Tibsovo (ivosidenib) • Yidafan (ivonescimab)
    3d
    Exploratory clinical study on preserving organs in patients with stage II-III non-small cell lung cancer(The Future Star) (ChiCTR2500115167)
    P4, N=598, Recruiting, Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
    New P4 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • ALK mutation
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Ensacove (ensartinib) • Ameile (aumolertinib) • AiRuiLi (adebrelimab)
    3d
    Neoadjuvant 160mg Furmonertinib and Cisplatin/Pemetrexed in EGFR Mutated Stage II-IIIB Resectable NSCLC: A prospective multicenter single-arm clinical study (ChiCTR2600116854)
    P2, N=27, Not yet recruiting, Army Medical Center of PLA; Army Medical Center of PLA
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • pemetrexed • Ivesa (firmonertinib)